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ABSTRACT 
 
Objective: To investigate whether beneficial and harmful effects of platelet glycoprotein (GP) IIb/IIIa 
receptor blockers in non-ST-elevation acute coronary syndromes (NSTE-ACS) depend on age. 
 
Methods: A meta-analysis of 6 trials of GP IIb/IIIa receptor blockers in NSTE-ACS patients (PRISM, 
PRISM-PLUS, PARAGON-A, PURSUIT, PARAGON-B, GUSTO IV-ACS; n=31,402) was performed. 
We applied multivariable logistic regression analyses to evaluate the drug effects on death or non-fatal 
MI at 30 days, and on major bleeding, by age subgroups (<60, 60-69, 70-79, ≥80 years). We quantified 
the reduction of death or MI as number needed to treat (NNT), and the increase of major bleeding as 
number needed to harm (NNH). 
 
Results: Subgroups had 11,155 (35%), 9,727 (31%), 8,468 (27%), and 2,049 (7%) patients, 
respectively. The relative benefit of GP IIb/IIIa receptor blockers did not differ significantly (p=0.5) 
across age subgroups (odds ratio [95% CI] for death or MI: 0.86 [0.74-0.99], 0.90 [0.80-1.02], 0.97 
[0.86-1.10], 0.90 [0.73-1.16]; overall 0.91 [0.86-0.99]). Odds ratios for major bleeding were 1.9 (1.3-
2.8), 1.9 (1.4-2.7), 1.6 (1.2-2.1), and 2.5 (1.5-4.1). Overall NNT was 105, and overall NNH was 90. The 
oldest had larger absolute increases in major bleeding, but also had the largest absolute reductions of 
death or MI. Patients ≥80 years had half of the NNT and a third of the NNH in comparison with patients 
<60 years. 
 
Conclusions: In patients with NSTE-ACS, the relative reduction of death or non-fatal MI with GP 
IIb/IIIa receptor blockers was independent of patient age. Larger absolute outcome reductions were 
seen in the elderly, but with a higher risk of major bleeding. A close monitoring of these patients is 
warranted. 
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Platelet glycoprotein (GP) IIb/IIIa receptor blockers decrease the risk of death or non-fatal myocardial 
infarction (MI) at 30 days in patients with non-ST elevation acute coronary syndromes (NSTE-ACS) 
who are not routinely scheduled for early revascularization [1-4]. Age is an important risk factor for 
these patients, and if the relative benefits of effective interventions are the same across age groups, 
physicians should treat the elderly even more aggressively than the younger, since the absolute benefit 
may be larger [5]. However, in clinical practice, the utilization of GP IIb/IIIa receptor blockers is lower 
among elderly patients [6]. 
 
 Elderly patients may be undertreated because of several reasons: they were underrepresented or 
excluded from randomized clinical trials (RCTs), clinicians may believe that benefits in younger may 
not generalize to the elderly, or they may be worried about harmful effects in elderly patients [5]. 
Researchers have argued that the benefit of GP IIb/IIIa receptor blockers is greater in younger patients 
[7], similar in old and younger patients [8], or greater in older patients given their higher baseline risk 
[5, 9].  
 
 Yet, it is difficult to determine how the efficacy of GP IIb/IIIa receptor blockers varies among 
age subgroups because most trials are not large enough to provide a reliable answer. Individual ACS 
trials have been inconclusive or even conflicting regarding the presence or absence of relative 
differences in drug effects across ages [10-15]. Usually, the patient population was only split in two age 
groups (e.g. <65 years, ≥65 years) [11, 13-15], and different primary endpoints were considered. An 
evaluation of the drug effects across age groups in a meta-analysis using individual data can better 
define its relative and absolute efficacies in older vs. younger patients. 
 
 One more issue is relevant in the interpretation of the effects of GP IIb/IIIa receptor blockers by 
age groups. The incorporation of harmful major bleeding rates in the evaluation of effects should be 
considered to further understand the net drug effectiveness across age strata [5, 9, 16]. 
 
 We investigated whether the relative effects of GP IIb/IIIa receptor blockers were consistent 
across age subgroups in non-ST-segment elevation ACS patients. Further, we evaluated whether the 
absolute benefits and harms differed across age subgroups. 
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METHODS 
Trial selection 
A meta-analysis of individual patient data was performed, including trials reported since 1990 with the 
following characteristics: randomization of patients with NSTE-ACS, comparison of a GP IIb/IIIa 
receptor blocker with placebo or control therapy, no-recommendation for early (<48h) coronary 
revascularization during study-drug infusion, and enrolment of at least 1000 patients. Six trials met the 
inclusion criteria -PRISM, PRISM-PLUS, PARAGON-A, PURSUIT, PARAGON-B, and GUSTO IV-
ACS- [10-15] with a total of 31,402 patients. Details of the trial designs are available elsewhere [3]. 
 
Patient baseline characteristics 
An electronic database consisting of data from individual patients in all eligible trials was available [3]. 
These data were checked for completeness, for internal consistency of patients’ records, and for 
consistency with the published reports. For this analysis, baseline characteristics regarded as important 
predictors of the outcome for which information was almost complete (i.e. less than 1% missing) were 
age, gender, diabetes, smoking, previous myocardial infarction [MI], previous heart failure [HF], 
previous coronary artery bypass surgery (CABG), previous percutaneous coronary intervention (PCI), 
and ST-segment depression. Other important predictors had more than 20% of missing data: blood 
pressure and heart rate were not recorded in the GUSTO IV-ACS trial (n=7800, 25%); and baseline 
creatine kinase MB (CK-MB) was missing in 7469 patients (24%) across different trials. Blood 
pressure, heart rate and CK-MB were used in addition to the other predictors in secondary analyses that 
yielded largely similar results. 
 
Endpoints 
For this analysis, the primary efficacy endpoint was defined a priori as the composite of death of any 
cause or non-fatal MI at 30 days. MI was part of the composite outcome of all trials. The MI definitions 
had subtle differences across trials regarding the CK-MB threshold [3] (Table 1). However, all trials 
had pre-specified definitions of MI [17, 18]. Secondary endpoints were: death; non-fatal MI; coronary 
artery bypass graft (CABG); percutaneous coronary intervention (PCI); and CABG or PCI. The primary 
harm endpoint was major bleeding within 30 days. Individual trial definitions of major bleeding had 
also at most subtle differences, and trial-specific definitions were retained [3]. We should acknowledge 
that death or non-fatal MI and major bleeding do not have the same utility, and therefore are not 
comparable events. A few patients with major bleeding die or have an MI within 30 days, and not all of 
the remaining patients have long-term negative outcomes. Determining the relative weights of these 
events is largely subjective. A recent review identified that the weight of a major bleeding related to a 
drug in the context of an acute coronary syndrome was 0.87, in comparison with the weight of death, 
which was equal to zero [19]. 
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Table 1: Definitions of primary efficacy and harm endpoints across trials 
 PRISM PRISM-
PLUS 
PARAGON-A       PURSUIT PARAGON-
B 
GUSTO 
ACS-IV 
Primary 
efficacy end 
point 
Death, MI 
or refractory 
ischemia at 
48 hours 
Death, MI 
or refractory 
ischemia at 
7 days 
Death of MI 
at 30 days 
Death or MI 
at 30 days 
Death, MI or 
severe, 
recurrent 
ischemia at 30 
days  
 
Death or MI 
at 30 days 
Required 
level of CK 
or CK-MB 
elevation in 
MI 
definition 
2xULN 2xULN; in 
relation to 
PCI: 
3xULN 
2xULN 1xULN; in 
relation to 
PCI: 3xULN; 
in relation to 
CABG: 
5xULN 
2xULN; in 
relation to 
PCI: 3xULN; 
in relation to 
CABG: 
5xULN 
 
3xULN 
Primary 
harm end 
point: 
major 
bleeding 
Intracraneal 
hemorrhage; 
bleeding 
leading to 
decrease in 
hemoglobin 
concentration 
≥50 g/L; or 
cardiac 
tamponade 
Intracraneal 
hemorrhage; 
bleeding 
leading to 
decrease in 
hemoglobin 
concentration 
≥40 g/L; 
bleeding 
requiring 
transfusion 
≥2 units 
blood; or 
bleeding 
requiring 
surgery  
Intracraneal 
hemorrhage; 
bleeding 
leading to 
hemodynamic 
compromise 
requiring 
intervention 
Intracraneal 
hemorrhage; 
bleeding 
leading to 
hemodynamic 
compromise 
requiring 
intervention 
Intracraneal 
hemorrhage; 
bleeding 
leading to 
hemodynamic 
compromise 
requiring 
intervention 
Intracraneal 
hemorrhage; 
bleeding 
leading to 
decrease in 
hemoglobin 
concentration 
≥ 50 g/L 
MI: myocardial infarction; CK: creatine kinase; CK-MB: creatine kinase fraction MB; ULN: Upper limit of normal;  
PCI: Percutaneous coronary intervention; CABG: Coronary-artery bypass graft 
 
 
Efficacy analysis by age 
We divided the patient data into four subgroups according to age: <60, 60-69, 70-79, and ≥80 years old. 
The decision to group patients in these intervals was made a priori, and was based on decade intervals 
of common clinical use. The choice of other cut-off points (e.g. quartiles) yielded similar results (not 
shown). Relative differences between GP IIb/IIIa receptor blockers and placebo/control on the primary 
endpoint by age subgroups were assessed, within each trial and across all trials. Logistic regression 
models were used, and odds ratios (OR) and corresponding 95% confidence intervals (95% CI) were 
calculated. To evaluate GP IIb/IIIa receptor blocker effect modification by age in each individual trial 
and in all trials, interaction tests were used [20]. These tests also evaluated heterogeneity of effects 
across trials. The effects of GP IIb/IIIa receptor blockers and the interactions were adjusted for the 
previously described predictors, for trial, and for potential differences in age-related trends between 
trials. These effects were combined using random effects calculations [21]. Heterogeneity of 
interactions across trials was evaluated with the random effects inverse variance model (with trial being 
the random effect) [22].  
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Benefit and harm of GP IIb/IIIa receptor blockers by age subgroups 
We performed analyses that incorporated the relation among the baseline risk (eBR, proportion of 
patients in the placebo/control group with the primary efficacy endpoint), the efficacy Odds Ratio 
(eOR), and the respective number needed to treat [NNT]. The calculation of NNT was done using eBR 
and eOR, with the formula: [1-eBR(1-eOR)]/ [eBR(1-eBR)(1-eOR)] [22]. The NNT is the number of 
patients who need to be treated in order to prevent one additional death or non-fatal MI. It is the inverse 
of the absolute risk reduction (ARR). Further, we looked at the relation among the baseline proportion 
of the primary harm endpoint in the placebo/control group (hBR), the harm Odds Ratio (hOR), and the 
respective number needed to harm [NNH]. The NNH was calculated using hBR and hOR, with the 
formula: [hBR(hOR-1)+1]/[hBR(1-hBR)(hOR-1)] [23]. The NNH is the number of patients who need 
to be treated in order to cause one major bleeding. It is the inverse of the absolute risk increase (ARI). 
The NNT and NNH calculations were done overall and by age subgroups.  
 
 
Role of the funding source 
The trials included in this analysis were sponsored by several pharmaceutical companies, which are 
mentioned in the main trial reports [10-15], and in the acknowledgements. This study was designed, 
conducted, and interpreted independently of the sponsors. These had the right to review the manuscript, 
but not censor the findings. No separate industrial grant was obtained for this investigation. 
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RESULTS 
 
Age subgroups and predictors 
Overall, 11,155 (35%) patients were < 60, 9,727 (31%) were 60-69, 8,468 (27%) were 70-79, and 2,049 
(7%) were ≥ 80 years-old. Baseline characteristics across age subgroups are shown in Table 2.  
 
Table 2. Patient characteristics by age subgroups. 
 
<60 years  
(n=11,155) 
 
  60-69 years 
(n=9,727) 
 70-79 years 
(n=8,468) 
≥80 years  
(n=2,049) 
 
N %  N %  N % 
 
N % 
Gender   
   Male 
 
  8275 
 
 74 
 
 
 
   6274 
 
65 
 
 
 
  4841   
  
57 
  
    997 
   
49 
Diabetes  
   Yes 
 
  1771 
 
 16 
  
   2360 
 
24 
 
  
 
  2269 
  
27 
  
    461 
   
  23 
Smoking  
   Never 
   Former 
   Current 
 
  3931 
  3144 
  4036 
 
 35 
 28 
 36 
  
   3439 
   3537 
   2709 
 
36 
37 
28 
  
  3269 
  3133 
  2015 
  
39 
37 
24 
  
    861 
    621 
    552 
   
  42 
  31 
  27 
Previous MI  
   Yes 
 
  3164 
 
 28 
  
   3445 
 
36 
  
  3162 
   
37 
  
    877 
   
  43 
Previous HF  
   Yes 
 
    578 
 
   5 
  
     962 
 
10 
  
  1191 
  
14 
  
    437 
   
  21 
Previous CABG  
   Yes 
 
  1088 
 
 10 
  
   1305 
 
13 
  
  1194 
  
14 
  
    185 
   
    9 
Previous PCI 
   Yes 
 
  1454 
 
 13 
  
   1251 
 
13 
  
    956 
   
11 
  
    162 
   
    8 
ST depression 
   Yes 
 
  5096 
 
 46 
  
   5475 
 
57 
  
  5441 
  
65 
  
  1403 
   
  69 
Trial 
   PRISM 
   PRISMPLUS 
   PARAGON-A 
   PURSUIT 
   PARAGON-B 
   GUSTO IV 
 
  1274  
    693 
    737 
  4082 
  1976 
  2393 
 
 11 
   6 
   7 
 37 
 18 
 21 
  
   1005 
     603 
     728 
   3553 
   1513 
   2325 
 
10 
  6 
  8 
37 
16 
24 
  
    781 
    495 
    631 
  2763 
  1374 
  2424 
 
  9 
  6 
  8 
33 
16 
29 
  
    172 
    124 
    183 
    550 
    362 
    658 
 
    8 
    6 
    9 
  27 
  18 
  32 
MI denotes myocardial infarction, HF: heart failure, CABG: coronary artery bypass graft, PCI: percutaneous 
coronary intervention, y: years. Differences among age subgroups were highly significant (p<0.001).
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Table 3. Treatment effect on various endpoints at 30 days according to age subgroups. 
 
 <60y (n=11,155)    60-69y (n=9,727)  70-79y (n=8,468)  ≥80y (n=2,049) 
 Events % OR*  
(95% CI) 
 Events %     OR 
    (95% CI) 
   Events  % OR 
(95% CI) 
 Events % OR 
(95% CI) 
Death† 
   GP IIb/IIIa 
   Placebo/Control 
 
  70 
  58 
  
1.1 
1.2  
 
0.86 
(0.61-1.23) 
  
  165   
  124   
 
2.9 
3.0 
 
0.98 
(0.77-1.24) 
  
  281 
  215 
 
5.6 
6.2 
 
0.91 
(0.75-1.09) 
  
  115 
    88 
 
9.5 
10.5 
 
0.90 
(0.67-1.21) 
Nonfatal MI‡ 
   GP IIb/IIIa 
   Placebo/Control 
 
 372 
 316 
 
5.7 
6.8 
 
0.83 
(0.72-0.97) 
  
  428 
  365   
 
7.6 
  8.8 
 
0.85 
(0.74-0.99) 
  
  437 
  299 
 
  8.8 
  8.6 
 
1.02 
(0.87-1.19) 
  
  112 
    85 
 
  9.3 
10.1 
 
0.91 
(0.68-1.23) 
Death or MI 
   GP IIb/IIIa 
   Placebo/Control 
 
 442 
 374 
 
6.8 
8.0 
 
0.86 
(0.74-0.99) 
  
  593 
  489 
 
10.6 
11.9 
 
0.90 
(0.80-1.02) 
  
  718 
  514 
 
14.4 
14.8 
 
0.97 
(0.86-1.10) 
  
  227 
  173 
 
18.8 
20.5 
 
0.90 
(0.73-1.16) 
CABG 
   GP IIb/IIIa 
   Placebo/Control 
 
 828 
 590 
 
12.7 
12.7 
 
1.00 
(0.90-1.13) 
  
  931 
  732 
 
16.6 
17.7 
 
0.92 
(0.83-1.03) 
  
  860 
  603 
 
17.2 
17.3 
 
0.99 
(0.88-1.11) 
  
  102 
    67 
 
8.5 
8.0 
 
1.07 
(0.77-1.47) 
PCI 
   GP IIb/IIIa 
   Placebo/Control 
 
 1839 
 1404 
 
28.3 
30.1 
 
0.92 
(0.84-0.99) 
  
1369 
  991 
 
24.4 
24.0 
 
1.02 
(0.93-1.12) 
  
  894 
  684 
 
17.9 
19.7 
 
0.89 
(0.80-1.00) 
  
  171 
  131 
 
14.2 
15.6 
 
0.90 
(0.70-1.15) 
CABG or PCI 
   GP IIb/IIIa 
   Placebo/Control 
 
 2618 
 1960 
 
40.3 
42.1 
 
0.93 
(0.86-1.00) 
  
2264 
1699 
 
40.4 
40.8 
 
0.97 
(0.89-1.05) 
  
1721 
1258 
 
34.5 
36.2 
 
0.93 
(0.85-1.02) 
  
  268 
  197 
 
22.2 
23.4 
 
0.93 
(0.76-1.15) 
Major bleeding 
   GP IIb/IIIa 
   Placebo/Control 
 
     90 
     35 
 
  1.5 
  0.8 
 
1.90 
(1.28-2.81) 
  
  118 
    46 
 
  2.3 
  1.1 
 
1.94 
(1.38-2.74) 
  
  174 
    80 
 
  3.8 
  2.3 
 
1.58 
(1.21-2.07) 
  
    63 
    19 
 
  5.7 
  2.3 
 
2.46 
(1.46-4.14) 
    * Odds ratio of treatment effect between GP IIb/IIIa and Placebo/Control, GP IIb/IIIa denotes platelet glycoprotein IIb/IIIa receptor blockers; †Death within 30 days; ‡ Non-fatal 
myocardial infarction in patients who survived at least 30 days. Number of patients per age group: <60 y: GP 6496, Placebo/control 4659; 60-69 y: GP 5602, Placebo/control 
4125; 70-79 y: GP 4991, Placebo/control 3477; >80 y: GP: 1207, Placebo/control: 842.  
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Table 4. Treatment effects on death or MI at 30 days according to age subgroups, by trial and overall.  
 
* Odds ratios of each age subgroup adjusted for trial. 
† Predictors included: age, gender, diabetes, smoking, previous MI, previous heart failure, previous CABG, previous PTCA, ST depression.  
‡ Odds ratios adjusted for predictors, and age trend. The interactions age by GP IIb/IIIa are significantly different among trials. p: p-value. 
 PRISM 
N=3,232 
PRISMPLUS 
N=1,915 
PARAGON-A 
N=2,282 
PURSUIT 
N=10,948 
PARAGON-B 
N=5,225 
GUSTO IV-ACS 
N=7,800 
TOTAL* 
N=31,402 
Age <60 years 
    OR (95% CI)    
 
 
1.13 
(0.66-1.96) 
 
0.98 
(0.54-1.78) 
 
1.65 
(0.83-3.30) 
 
0.72 
(0.59-0.88) 
 
0.90 
(0.64-1.27) 
 
1.01 
(0.65-1.55) 
 
0.86 
(0.74-0.99) 
Age 60-69 years 
    OR (95% CI) 
 
 
0.86 
(0.53-1.38) 
 
0.58 
(0.35-0.96) 
 
0.87 
(0.55-1.39) 
 
0.93 
(0.77-1.20) 
 
0.81 
(0.59-1.12) 
 
1.19 
(0.85-1.67) 
 
0.90 
(0.80-1.02) 
Age 70-79 years 
    OR (95% CI) 
 
0.63 
(0.36-1.09) 
 
1.02 
(0.61-1.70) 
 
0.83 
(0.53-1.31) 
 
0.91 
(0.76-1.11) 
 
1.11 
(0.82-1.50) 
 
1.15 
(0.88-1.50) 
 
0.97 
(0.86-1.10) 
Age ≥80 years 
    OR (95% CI) 
 
 
0.45 
(0.19-1.07) 
 
0.94 
(0.39-2.27) 
 
0.82 
(0.37-1.81) 
 
1.27 
(0.87-1.86) 
 
0.84 
(0.48-1.47) 
 
0.80 
(0.52-1.22) 
 
0.90 
(0.73-1.16) 
All subgroups, 
adjusted for 
predictors† 
 
0.80 
(0.60-1.06) 
 
0.83 
(0.62-1.11) 
 
0.95 
(0.72-1.25) 
 
0.88 
(0.79-0.98) 
 
0.92 
(0.78-1.10) 
 
1.07 
(0.90-1.27) 
 
0.91 
(0.86-0.99) 
Age by GP 
IIb/IIIa 
Interaction  
(p)‡ 
 
 
0.01 
 
 
0.77 
 
 
0.15 
 
 
0.03 
 
 
0.92 
 
 
0.52 
 
 
0.15 
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The proportion of women and of patients with a history of diabetes, MI or HF, and ST depression 
increased with age. Further, patients ≥80 years had lower proportions of previous revascularisation 
procedures than younger patients. The proportion of patients older than 70 years ranged between 30% 
in the PURSUIT and PRISM trials and 40% in the GUSTO IV-ACS trial. 
 
Endpoints at 30 days by age subgroups 
The overall adjusted relative reduction in the odds of death or MI at 30 days was 9% (OR 0.91; 95% CI 
[0.85-0.99]). There was no difference in the relative benefit of GP IIb/IIIa receptor blockers across age 
subgroups (p for interaction = 0.5) and this was true also for secondary efficacy endpoints (Table 3). 
Interestingly, the ratio of non-fatal MI over death decreased with increasing age. The overall adjusted 
relative increase in the odds of major bleeding was 83% (OR 1.83 [1.5-2.2]). This was especially high 
for patients ≥80 years (OR 2.5 [1.5-4.1]), but there were no significant differences across ages (p for 
interaction=0.3) (Table 3).  
 
Benefit of GP IIb/IIIa receptor blockers per trial by age subgroups 
With regard to the incidence of death or non-fatal MI, two trials showed significantly different relative 
effects across age subgroups, but in opposite directions (Table 4). The PRISM trial patients had a clear 
gradient of GP IIb/IIIa receptor blocker effect across ages: older patients had larger odds reductions 
than younger ones (p for interaction=0.01). Conversely, younger PURSUIT patients had larger odds 
reductions than the older ones (p for interaction=0.03). The interactions between GP IIb/IIIa receptor 
blockers and age subgroup were heterogeneous across trials (p=0.002). 
 
Benefit and harm of GP IIb/IIIa receptor blocker across age subgroups 
The absolute risk of death or MI at 30 days correlated with age, varying from 8% in the youngest (<60 
years) to 21% in the oldest group (≥80 years). Major bleeding at 30 days also correlated with age, from 
0.8% in the youngest to 2.3% in the oldest. For the overall relative reduction in the odds of death or MI 
of 9%, the NNT was 105. For the overall relative increase in the odds of major bleeding of 83%, the 
NNH was 90.  
The oldest patients had the largest absolute reductions of death or MI, but also had larger 
absolute increases in major bleeding. Patients younger than 70 years had higher NNTs and NNHs (149 
and 163 for those younger than 60 years, and 105 and 110 for those between 60 and 69 years) than 
those older than 70 years (87 and 55 for those between 70 and 79 years, and 67 and 56 for those older 
than 80 years). Figure 1 shows the absolute event rate difference between GP IIb/IIIa receptor blocker 
and placebo/control arms across age subgroups. We noted a rather larger harm in patients ≥70 years and 
a somewhat variable benefit across all age subgroups. 
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DISCUSSION 
 
In patients with ACS without ST elevation, the relative reduction in the odds of death or MI at 30 days 
with GP IIb/IIIa receptor blockers was largely independent of age. The oldest patients had about 3-fold 
the baseline risk of the youngest ones, not only for death or MI, but also for major bleeding. In the 
oldest patients, the use of GP IIb/IIIa receptor blockers yielded larger absolute reductions of death/MI, 
but also larger absolute increases in major bleeding rates in comparison with the youngest patients.  
 
 This meta-analysis had more statistical power than individual trials to explore how the GP 
IIb/IIIa receptor blocker effects vary by age [7-9, 24]. Individual trials did not report these effects in 
detail across similar age subgroups [10, 11, 13-15], and they analyzed different endpoints. Previous 
analyses of the age effects in single trials have yielded inconclusive results [25]. Only the PURSUIT 
and GUSTO IV-ACS reported the same primary endpoint as we used in this paper. Also, these analyses 
did not adjust for important predictors of the primary endpoint. We found that the PRISM and the 
PURSUIT trials showed significant differential relative effects of GP IIb/IIIa receptor blockers across 
ages, but differences were in the opposite direction. We do not fully understand this phenomenon. We 
speculate that it could be related to the doses used as well as the duration of the study drug infusion. 
This might have resulted in different levels of platelet inhibition in the PRISM trial (where the dose was 
later shown to produce suboptimal platelet inhibition in young patients) as compared to the PURSUIT 
trial (where the dose was not adjusted for older age or modest renal impairment), which might have had 
different consequences in younger and older patients.  
 
The effects of other antithrombotics have been evaluated in elderly patients with unstable 
angina or NSTE-ACS [9]. The low molecular weight heparin enoxaparin, compared with unfractionated 
heparin, appeared to have greater relative and absolute benefit in patients aged 65 years and older, as 
compared with younger patients. When comparing clopidogrel plus aspirin to aspirin alone, there was a 
consistent 20% relative reduction in cardiovascular death, myocardial infarction, or stroke in both 
elderly and younger patients. For GP IIb/IIIa receptor blockers, we found an equivalent relative benefit 
across age subgroups, which translated into a greater absolute benefit in older in comparison with 
younger patients. 
 
In order to describe the relative gain in primary efficacy end points by age subgroups, we 
defined a ratio of reduction of non-fatal MIs to reduction of deaths. For instance, a ratio higher than 1 
shows a larger benefit in reduction of non-fatal MIs in comparison to reduction of deaths. Given that the 
ratio of non-fatal MI to death decreased with increased age, the use of GP IIb/IIIa receptor blockers in 
the oldest likely aborted more deaths than non-fatal MIs.  
 
 Most trials, meta-analyses, and systematic reviews have neglected the contribution of major 
bleeding rates in the evaluation of the net GP IIb/IIIa receptor blocker effectiveness across age 
subgroups in NSTE-ACS patients [1-4, 10-15, 26-31]. Elderly patients have higher absolute risks of 
major bleeding [6, 32]. Therefore, the interpretation of the overall GP IIb/IIIa receptor blocker efficacy 
needs to incorporate this harm. Although there was a trend for increasing bleeding risk with increasing 
age, this was nowhere close to being statistically significant, and it should be interpreted cautiously 
given the small number of patients in the highest age category. 
 
 An appropriate dosing of GP IIb/IIIa receptor blockers is a requisite to obtain a higher benefit 
and a lower harm in elderly NSTE-ACS patients. The CRUSADE registry demonstrated that GP IIb/IIIa 
receptor blockers were underutilized and mis-dosed in elderly patients, who are at higher risk for 
adverse cardiac events [33]. An essential factor that increases the risk of major bleeding in elderly 
patients is low renal function, which is associated with higher serum levels of GP IIb/IIIa receptor 
blockers. Doses used in early trials were more aggressive than currently recommended doses, which are 
adjusted for renal dysfunction. Thus, elderly NSTE-ACS patients should receive adequate doses of GP 
IIb/IIIa receptor blockers to obtain the expected clinical benefit, and these doses should be adjusted for 
their level of renal function to avoid major bleeding events.  
 
 A recent decision analysis evaluated the efficacy of an unspecified potential drug on survival in 
patients with MI and unstable angina [5], and included serious adverse events (fatal complications) as 
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an element of the evaluation of benefit-risk balance by age-related baseline risks. The authors used a 
registry database, and a hard primary endpoint (mortality at 1 year). The estimate of effectiveness was 
larger than in our randomized data (relative risk reduction 25%, absolute risk reduction 2%), and the 
registry population was more heterogeneous in risk (baseline risk of 2.3% in the youngest vs.27% in the 
oldest). They defined a threshold beyond which the treatment benefit would be outclassed by the 
treatment harm, and found that the fatal complication rate would have to be sevenfold greater in the 
oldest compared with the youngest age group to outweigh the survival benefits associated with 
treatment. These results need to be interpreted cautiously given that most major events in these patients 
do not lead to death. Moreover, retrospective observational data may sometimes inflate estimates of 
treatment efficacy [34].  
 
 Some limitations should be acknowledged. First, even with over 30,000 randomised patients, 
subtle age interactions could have been missed, especially for rare events such as death. We did not see 
any age interactions for death based on the available data (not reported) and the clinical significance of 
subtle interactions is debatable. Second, the total number of patients in the ≥80 age subgroup (n=2049) 
was small, and less than 25% of each of the other three groups (n>8400). Third, a substantial amount of 
missing values for a few important predictors (blood pressure, heart rate, CK-MB) limited some 
possibilities of adjusted analysis. However, the results with imputed data yielded similar conclusions 
(not shown). Fourth, additional research into the appropriate weighting of events is needed, that can 
allow a more direct comparison between benefits and harms.  
 
A series of nuances should be considered in interpreting these results. The trials included broad 
populations of patients with ACS. Through analysis of subgroups, it seems evident that higher risk 
patients, such as those with positive troponins, diabetes, and perhaps ST segment depression, achieve 
the greatest benefit. Further, it is likely that patients treated with the aggressive revascularisation 
strategy achieve more benefit than those treated with the conservative strategy. The trials themselves 
were heterogeneous, as GUSTO IV-ACS showed no benefit and perhaps a detriment of abciximab, and 
PURSUIT used a very liberal definition of myocardial infarction that minimized the differences 
between eptifibatide and placebo. Finally, the category of major bleeding overestimates risk relative to 
the risk of blood transfusion, which is a more direct measure of risk and occurs less frequently 
(Mahaffey KW et al., Circulation, in press). The EARLY ACS trial is enrolling patients without age 
limits, it is testing whether the benefit of antithrombotic drugs is similar between elderly and young 
patients, and it is also addressing each of the above issues [35]. Allowing for these caveats, our analysis 
provides estimates for NNTs and NNHs by age subgroups that may be used in clinical decision making 
for the use of GP IIb/IIIa receptor blockers in NSTE-ACS patients. 
 
 In conclusion, the relative risk reduction of death or MI with GP IIb/IIIa receptor blocker is 
independent of age in patients with non-ST-elevation acute coronary syndromes. Larger absolute 
reductions of death or MI were observed in the oldest in comparison with the youngest patients, as well 
as larger absolute increases in major bleeding rates. Attention should be given to optimizing the benefit 
to elderly patients without increasing bleeding, by ensuring that doses adjusted for renal function are 
given. Moreover, elderly patients should be monitored more intensively. 
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FIGURE LEGEND 
 
Figure 1. Absolute event rate differences between treatment arms (GP IIb/IIIa vs. 
placebo/control) by age subgroups in beneficial (death or myocardial infarction) and harmful 
(major bleeding) endpoints. GP IIb/IIIa denotes platelet glycoprotein IIb/IIIa receptor blockers. 
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